Heart rate as a target of treatment of chronic heart failure

Journal of Cardiology

Volumn 60, Issue 2, 2012, Pages 86-90

  Hori, Masatsugu ^a   Okamoto, Hiroshi ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

Author keywords

Blocker treatment; Chronic heart failure; Resting heart rate

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; METOPROLOL;

AUTONOMIC NERVE; BLOOD PRESSURE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; EXCITATION CONTRACTION COUPLING; EXERCISE; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HEART RATE VARIABILITY; HOMEOSTASIS; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); MORTALITY; NERVE CONDUCTION; NEUROTRANSMISSION; PRESSORECEPTOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TACHYCARDIA; TACHYCARDIA INDUCED CARDIOMYOPATHY; VAGUS NERVE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHRONIC DISEASE; DISEASE PROGRESSION; HEART FAILURE; HEART RATE; HUMANS;

EID: 84865383976     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.06.013     Document Type: Review

References (55)

1. Bonnemeier H., Richardt G., Potratz J., Wiegand U.K., Brandes A., Kluge N., Katus H.A. Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability. J Cardiovasc Electrophysiol 2003, 14:791-799.
2. Palatini P., Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004, 26:637-644.
3. Benetos A., Thomas F., Bean K., Albaladejo P., Palatini P., Guize L. Resting heart rate in older people: a predictor of survival to age 85. J Am Geriatr Soc 2003, 51:284-285.
4. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000, 13(1 Pt. 2):3S-10S.
5. Jouven X., Empana J.P., Schwartz P.J., Desnos M., Courbon D., Ducimetière P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005, 352:1951-1958.
6. Levine H.J. Rest heart rate and life expectancy. J Am Coll Cardiol 1997, 30:1104-1106.
7. Levy R.L., White P.D., Stroud W.D. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945, 129:585-588.
8. Kannel W.B., Kannel C., Paffenbarger R.S., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
9. Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005, 26:967-974.
10. Kolloch R., Legler U.F., Champion A., Cooper-Dehoff R.M., Handberg E., Zhou Q., Pepine C.J. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008, 29:1327-1334.
11. Antoni M.L., Boden H., Delgado V., Boersma E., Fox K., Schalij M.J., Bax J.J. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2012, 33:96-102.
12. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821. BEAUTIFUL investigators.
13. Swedberg K., Komajda M., Böhm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L., SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
14. Mølgaard H., Sørensen K.E., Bjerregaard P. Circadian variation and influence of risk factors on heart rate variability in healthy subjects. Am J Cardiol 1991, 68:777-784.
15. Novak V., Novak P., de Champlain J., Le Blanc A.R., Martin R., Nadeau R. Influence of respiration on heart rate and blood pressure fluctuations. J Appl Physiol 1993, 74:617-626.
16. Fouad F.M., Tarazi R.C., Ferrario C.M., Fighaly S., Alicandri C. Assessment of parasympathetic control of heart rate by a noninvasive method. Am J Physiol 1984, 246(6 Pt. 2):H838-H842.
17. Eckberg D.L., Drabinsky M., Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971, 285:877-883.
18. Casolo G., Balli E., Fazi A., Gori C., Freni A., Gensini G. Twenty-four-hour spectral analysis of heart rate variability in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1991, 67:1154-1158.
19. Arai Y., Saul J.P., Albrecht P., Hartley L.H., Lilly L.S., Cohen R.J., Colucci W.S. Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol 1989, 256(1 Pt. 2):H132-H141.
20. Guo G.B., Abboud F.M. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol 1984, 246(1 Pt. 2):H80-H89.
21. Potter E.K., Ulman L.G. Neuropeptides in sympathetic nerves affect vagal regulation of the heart. News Physiol Sci 1994, 9:174-177.
22. Packer D.L., Bardy G.H., Worley S.J., Smith M.S., Cobb F.R., Coleman R.E., Gallagher J.J., German L.D. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986, 57:563-570.
23. Cruz F.E., Cheriex E.C., Smeets J.L., Atié J., Peres A.K., Penn O.C., Brugada P., Wellens H.J. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 1990, 16:739-744.
24. Umana E., Solares C.A., Alpert M.A. Tachycardia-induced cardiomyopathy. Am J Med 2003, 114:51-55.
25. Rabbani L.E., Wang P.J., Couper G.L., Friedman P.L. Time course of improvement in ventricular function after ablation of incessant automatic atrial tachycardia. Am Heart J 1991, 121(3 Pt. 1):816-819.
26. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Kay G.N., Le Huezey J.Y., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann L.S. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57:e101-e198.
27. Wilson J.R., Douglas P., Hickey W.F., Lanoce V., Ferraro N., Muhammad A., Reichek N. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987, 75:857-867.
28. Shannon R.P., Komamura K., Shen Y.T., Bishop S.P., Vatner S.F. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 1993, 265(3 Pt. 2):H801-H809.
29. Spinale F.G., Tomita M., Zellner J.L., Cook J.C., Crawford F.A., Zile M.R. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991, 261(2 Pt. 2):H308-H318.
30. Reinkober J., Tscheschner H., Pleger S.T., Most P., Katus H.A., Koch W.J., Raake P.W. Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade. Gene Ther 2012, 19:686-693.
31. Sajadieh A., Nielsen O.W., Rasmussen V., Hein H.O., Abedini S., Hansen J.F. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004, 25:363-370.
32. Yano M., Ono K., Ohkusa T., Suetsugu M., Kohno M., Hisaoka T., Kobayashi S., Hisamatsu Y., Yamamoto T., Kohno M., Noguchi N., Takasawa S., Okamoto H., Matsuzaki M. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation 2000, 102:2131-2136.
33. Couvreur N., Tissier R., Pons S., Chetboul V., Gouni V., Bruneval P., Mandet C., Pouchelon J.L., Berdeaux A., Ghaleh B. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J 2010, 31:1529-1537.
34. Albaladejo P., Asmar R., Safar M., Benetos A. Association between 24-hour ambulatory heart rate and arterial stiffness. J Hum Hypertens 2000, 14:137-141.
35. Benetos A., Adamopoulos C., Bureau J.M., Temmar M., Labat C., Bean K., Thomas F., Pannier B., Asmar R., Zureik M., Safar M., Guize L. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002, 105:1202-1207.
36. Giannoglou G.D., Chatzizisis Y.S., Zamboulis C., Parcharidis G.E., Mikhailidis D.P., Louridas G.E. Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. Int J Cardiol 2008, 126:302-312.
37. Heidland U.E., Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001, 104:1477-1482.
38. Custodis F., Baumhäkel M., Schlimmer N., List F., Gensch C., Böhm M., Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:2377-2387.
39. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
40. Doughty R.N., Whalley G.A., Walsh H.A., Gamble G.D., López-Sendón J., Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004, 109:201-206. CAPRICORN Echo Substudy Investigators.
41. Metra M., Nodari S., Parrinello G., Giubbini R., Manca C., Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003, 145:292-299.
42. Hori M., Sasayama S., Kitabatake A., Toyo-oka T., Handa S., Yokoyama M., Matsuzaki M., Takeshita A., Origasa H., Matsui K., Hosoda S. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004, 147:324-330. MUCHA Investigators.
43. Hori M., Okamoto H., Matsuzaki M., Izumi T., Yamazaki T., Yoshikawa T., Tsutsui H., Fujio Y., Azuma J., Ohashi Y., Kitabatake A. Randomized trial to optimize the dose and efficacy of beta-blocker in systolic heart failure: Japanese Chronic Heart Failure (J-CHF) study. Late Breaking Clinical Trial at 82th AHA Meeting in Orlando 2009, on behalf of the J-CHF investigators and patients.
44. Lechat P., Hulot J.S., Escolano S., Mallet A., Leizorovicz A., Werhlen-Grandjean M., Pochmalicki G., Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001, 103:1428-1433.
45. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
46. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L. Carvedilol prospective randomized cumulative survival study group effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
47. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
48. Simon G., Johnson M.L. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension. Clin Exp Hypertens 1993, 15:501-509.
49. Stoschitzky K., Stoschitzky G., Brussee H., Bonelli C., Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006, 106:199-206.
50. Patrianakos A.P., Parthenakis F.I., Mavrakis H.E., Diakakis G.F., Chlouverakis G.I., Vardas P.E. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 2005, 150:985.
51. Nessler J., Nessler B., Kitliński M., Gackowski A., Piwowarska W., Stepniewski M. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol. Kardiol Pol 2008, 66:144-151.
52. Jorde U.P., Vittorio T.J., Kasper M.E., Arezzi E., Colombo P.C., Goldsmith R.L., Ahuja K., Tseng C.H., Haas F., Hirsh D.S. Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: time to pace?. Eur J Heart Fail 2008, 10:96-101.
53. Olsson L.G., Swedberg K., Clark A.L., Witte K.K., Cleland J.G. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J 2005, 26:778-793.
54. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816. BEAUTIFUL Investigators.
55. Thackray S.D., Ghosh J.M., Wright G.A., Witte K.K., Nikitin N.P., Kaye G.C., Clark A.L., Tweddel A., Cleland J.G. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006, 152:713.e9-713.e13.